Stock listing

Frankfurt:NKB2 TG Therapeutics, Inc. Aktie

German listing (Frankfurt) of TG Therapeutics, Inc. · home listing NASDAQ:TGTX

Follow TG Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · FWB:NKB2

€54.80 EUR +6.80 (+14.2%)

Close on Oct 30, 2026

Day range
€51.20 – €54.80 EUROct 30, 2026
TG Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TGTX · Home$59.95 USD-1.23 (-2.0%)2,574,106$61.01$63.60$59.59$61.18Close on Nov 2, 2026
Frankfurt:NKB2€54.80 EUR+6.80 (+14.2%)—€51.20€54.80€51.20€48.00Close on Oct 30, 2026
Ticker
Frankfurt:NKB2
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • TG Therapeutics (NASDAQ:TGTX) Q3 2026 Earnings Call

    Mon, Nov 09, 2026 · 8:30 AM ET

    Register

Replays

  • TG Therapeutics (NASDAQ:TGTX) Q2 2026 Earnings Call

    Mon, Aug 03, 2026 · 8:30 AM ET

    Watch Transcript

  • TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 8:30 AM ET

    Watch Transcript

  • TG Therapeutics (NASDAQ:TGTX) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026

Oct 23, 2026

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

Oct 21, 2026

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

Oct 12, 2026

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

Oct 8, 2026

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Aug 3, 2026

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

Jul 29, 2026

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Jul 6, 2026

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Jun 9, 2026

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Jun 3, 2026

All TG Therapeutics, Inc. news

Decks

TG Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 233 in all · newest Oct 23, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Aug 3, 2026
Decks
19 decks · latest Oct 23, 2026

Where TG Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TGTX · Home listingNASDAQUnited StatesUSD
gettex:NKB2gettexGermanyEUR
LS Exchange:A1JXW7LS ExchangeGermanyEUR
Tradegate:NKB2TradegateGermanyEUR
BOATS:TGTXBOATSUnited StatesUSD
Lang & Schwarz:A1JXW7Lang & SchwarzGermanyEUR
Milan:1TGTXMilanItalyEUR
Frankfurt:NKB2 · This pageFrankfurtGermanyEUR
LSE:0VGILSEUnited KingdomUSD
BX Swiss:NKB2BX SwissSwitzerlandCHF
Dusseldorf:NKB2DusseldorfGermanyEUR
Hamburg:NKB2HamburgGermanyEUR
Munich:NKB2MunichGermanyEUR
Stuttgart:NKB2StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about TG Therapeutics, Inc.